Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

Proyecto PDC2022-133991-I00 financiado por MICIU/AEI/10.13039/501100011033 y por la Unión Europea Next GenerationEU/ PRTR

IP: Rafael Simó Canonge
Collaborators: Anna Duarri Piqué, Cristina Hernández Pascual, Hugo Ramos Abellan, Patricia Bogdanov Baruj
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 128570
Reference: PDC2022-133991-I00
Duration: 01/12/2022 - 30/11/2024

Ministerio de Ciencia

Utilidad de la inteligencia artificial en el análisis de imágenes de retina para identificar los pacientes con mayor riesgo de progresión de la retinopatía diabética en el mundo real.

IP: Olga Simó Servat
Collaborators: Rafael Simó Canonge, Cristina Hernández Pascual
Funding agency: Sociedad Española de Diabetes
Funding: 20000
Reference: SED/PJ.JOVES.INVEST/2022/SIMO
Duration: 29/05/2023 - 28/05/2024

Administración tópica (colirio) de sitagliptina: una nueva estrategia para tratar la neurodegeneración de la retina en el glaucoma (GlauSit@)

IP: Rafael Simó Canonge
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 121900
Reference: PDC2021-121638-I00
Duration: 01/12/2021 - 30/11/2023

Ministerio de Ciencia

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Andrea Casal Pardo

Andrea Casal Pardo

Predoctoral researcher
Kidney Physiopathology
Read more
Sergi Martí Beltran

Sergi Martí Beltran

Pneumology
Read more
Belén Moro

Belén Moro

P. Management and Admin. Technical specialist
Pre-Award Project Unit
Competitive Research Directorate
Read more
Miriam  Moratal  Cloquell

Miriam Moratal Cloquell

General Surgery
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.